Vanguard Capital Management
EW icon

Vanguard Capital Management’s Edwards Lifesciences EW Stock Holding History

Vanguard Capital Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.4B Sell
37,615,952
-111,840
-0.3% -$9.37M 0.07% 234
2026
Q1 		$3.02B Buy
+37,727,792
New +$3.11B 0.07% 227

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
Aristotle Capital Management
Aristotle Capital Management Los Angeles, California $47.7B AUM 13.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Vanguard Capital Management's EW Position: Q2 2026 in Review

Vanguard Capital Management reduced its Edwards Lifesciences (EW) stake by 0.3% in Q2 2026, selling an estimated $9.37M and leaving 37,615,952 shares worth $3.4B. The position accounts for 0.07% of the portfolio, ranked #234.

Vanguard Capital Management first reported a position in EW in Q1 2026 and has held it in 2 quarters since. 1,259 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Vanguard Capital Management held 37,615,952 shares of Edwards Lifesciences worth $3.4B as of Q2 2026.
  • Vanguard Capital Management sold 111,840 Edwards Lifesciences shares in Q2 2026, an estimated $9.37M.
  • Edwards Lifesciences made up 0.07% of Vanguard Capital Management's portfolio in Q2 2026, its #234 holding.
  • Vanguard Capital Management first reported a position in Edwards Lifesciences in Q1 2026 and has held it in 2 quarters since.
  • 1,259 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.